Arrowpoint Investment Partners Singapore Pte. Ltd. Invests $705,000 in McKesson Corporation $MCK

Arrowpoint Investment Partners Singapore Pte. Ltd. bought a new stake in McKesson Corporation (NYSE:MCK) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 912 shares of the company’s stock, valued at approximately $705,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of MCK. Obsidian Personal Planning Solutions LLC increased its stake in McKesson by 2.9% in the third quarter. Obsidian Personal Planning Solutions LLC now owns 426 shares of the company’s stock valued at $346,000 after acquiring an additional 12 shares during the last quarter. IAM Advisory LLC grew its position in McKesson by 0.3% during the third quarter. IAM Advisory LLC now owns 3,908 shares of the company’s stock valued at $3,019,000 after acquiring an additional 13 shares during the last quarter. PDS Planning Inc raised its stake in shares of McKesson by 1.1% during the third quarter. PDS Planning Inc now owns 1,209 shares of the company’s stock worth $934,000 after acquiring an additional 13 shares in the last quarter. Berkshire Asset Management LLC PA lifted its holdings in shares of McKesson by 4.6% in the 3rd quarter. Berkshire Asset Management LLC PA now owns 294 shares of the company’s stock worth $227,000 after acquiring an additional 13 shares during the last quarter. Finally, Goldstein Advisors LLC boosted its stake in shares of McKesson by 4.4% in the 3rd quarter. Goldstein Advisors LLC now owns 334 shares of the company’s stock valued at $258,000 after purchasing an additional 14 shares in the last quarter. Hedge funds and other institutional investors own 85.07% of the company’s stock.

Insider Transactions at McKesson

In related news, EVP Thomas L. Rodgers sold 276 shares of the stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $816.18, for a total value of $225,265.68. Following the completion of the sale, the executive vice president directly owned 2,268 shares of the company’s stock, valued at approximately $1,851,096.24. This represents a 10.85% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Leann B. Smith sold 190 shares of the stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $945.00, for a total transaction of $179,550.00. Following the completion of the sale, the executive vice president directly owned 2,989 shares of the company’s stock, valued at approximately $2,824,605. This trade represents a 5.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 3,868 shares of company stock valued at $3,743,820. Company insiders own 0.08% of the company’s stock.

McKesson Stock Down 0.3%

Shares of NYSE MCK opened at $941.51 on Friday. The firm’s 50-day moving average price is $893.90 and its 200-day moving average price is $824.34. McKesson Corporation has a 52-week low of $637.00 and a 52-week high of $999.00. The company has a market cap of $115.33 billion, a PE ratio of 27.08, a PEG ratio of 1.52 and a beta of 0.38.

McKesson (NYSE:MCK) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $9.34 earnings per share for the quarter, beating analysts’ consensus estimates of $9.19 by $0.15. The company had revenue of $106.16 billion for the quarter, compared to the consensus estimate of $105.98 billion. McKesson had a net margin of 1.09% and a negative return on equity of 338.97%. The firm’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $8.03 earnings per share. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. As a group, equities research analysts anticipate that McKesson Corporation will post 32.77 EPS for the current fiscal year.

McKesson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 1st. Investors of record on Monday, March 2nd will be issued a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Monday, March 2nd. McKesson’s dividend payout ratio (DPR) is currently 9.43%.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on MCK. Weiss Ratings downgraded shares of McKesson from a “buy (a-)” rating to a “buy (b+)” rating in a research note on Thursday, February 5th. Barclays boosted their target price on McKesson from $960.00 to $1,050.00 and gave the company an “overweight” rating in a research note on Wednesday, February 18th. Morgan Stanley restated an “overweight” rating and set a $966.00 target price on shares of McKesson in a report on Thursday, January 29th. Wells Fargo & Company lifted their price target on McKesson from $914.00 to $925.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 5th. Finally, Evercore restated an “outperform” rating on shares of McKesson in a research report on Thursday, March 5th. Thirteen analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, McKesson has an average rating of “Moderate Buy” and a consensus price target of $960.93.

About McKesson

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.